Feb 29 |
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
|
Feb 27 |
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
|
Feb 7 |
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
|
Jan 23 |
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
|
Jan 15 |
Those who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 247%
|
Dec 19 |
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
|
Dec 18 |
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
|
Nov 27 |
Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives
|
Nov 9 |
Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
|